Literature DB >> 12050368

Differential effect of murine alpha/beta interferon transgenes on antagonization of herpes simplex virus type 1 replication.

Peter Härle1, Vanessa Cull, Martin-Paul Agbaga, Robert Silverman, Bryan R G Williams, Cassandra James, Daniel J J Carr.   

Abstract

Alpha/beta interferons (IFN-alpha/beta) are potent, endogenous antiviral cytokines that suppress the replication of RNA and DNA viruses, including herpes simplex virus type 1 (HSV-1). The present study compared the efficacies of IFN-alpha/beta transgenes, including IFN-alpha1, -alpha4, -alpha5, -alpha6, -alpha9, and -beta, against HSV-1 infection. L929 cells transfected with the IFN-alpha/beta transgenes produced similar levels of IFN, as measured by bioassay and enzyme-linked immunosorbent assay. In addition, transfected cells were less susceptible to HSV-1 infection than were cells transfected with a plasmid vector control. The murine IFN-beta plasmid construct exhibited the greatest reduction, while the murine IFN-alpha5 transgene showed a modest inhibitory effect in viral titers recovered from the supernatants of transfected, infected L929 cultures. Consistent with this observation, the IFN-beta transgene antagonized viral transcript levels, including infected cell protein 27, thymidine kinase, and glycoprotein B, to a greater extent than did the IFN-alpha transgenes at 6 to 10 h postinfection as determined by real-time PCR. Cells transfected with the IFN-alpha4, IFN-alpha9, or IFN-beta transgenes showed the greatest reduction in viral protein expression relative to the other transfected cells, which was associated with increased STAT1 expression. The absence of the IFN-responsive protein kinase R (PKR) gene completely abrogated the antiviral induction by all IFN-alpha/beta against HSV-1. In the absence of RNase L, viral yields were increased 10-fold, but the antiviral effect of IFN was either unaffected or enhanced. These results suggest that the predominant IFN-mediated, antiviral pathway during HSV-1 infection taken by IFN-alpha/beta in L929 cells utilizes PKR.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12050368      PMCID: PMC136290          DOI: 10.1128/jvi.76.13.6558-6567.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  75 in total

1.  Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene.

Authors:  D A Leib; M A Machalek; B R Williams; R H Silverman; H W Virgin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

2.  Herpes simplex virus type 1 suppresses the interferon signaling pathway by inhibiting phosphorylation of STATs and janus kinases during an early infection stage.

Authors:  S Yokota ; N Yokosawa; T Kubota; T Suzutani; I Yoshida; S Miura; K Jimbow; N Fujii
Journal:  Virology       Date:  2001-07-20       Impact factor: 3.616

3.  Herpes simplex virus ICP0 mutants are hypersensitive to interferon.

Authors:  K L Mossman; H A Saffran; J R Smiley
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

Review 4.  Noncytolytic control of viral infections by the innate and adaptive immune response.

Authors:  L G Guidotti; F V Chisari
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

5.  Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/Caspase-8 death signaling pathway.

Authors:  S Balachandran; P C Roberts; T Kipperman; K N Bhalla; R W Compans; D R Archer; G N Barber
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

6.  Activation of p38 mitogen-activated protein kinase and c-Jun NH(2)-terminal kinase by double-stranded RNA and encephalomyocarditis virus: involvement of RNase L, protein kinase R, and alternative pathways.

Authors:  M S Iordanov; J M Paranjape; A Zhou; J Wong; B R Williams; E F Meurs; R H Silverman; B E Magun
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

7.  Protective T-cell-based immunity induced in neonatal mice by a single replicative cycle of herpes simplex virus.

Authors:  M Franchini; C Abril; C Schwerdel; C Ruedl; M Ackermann; M Suter
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

8.  Participation of type I interferon in the decreased virulence of the UL13 gene-deleted mutant of herpes simplex virus type 1.

Authors:  T Shibaki; T Suzutani; I Yoshida; M Ogasawara; M Azuma
Journal:  J Interferon Cytokine Res       Date:  2001-05       Impact factor: 2.607

9.  Effect of deficiency of the double-stranded RNA-dependent protein kinase, PKR, on antiviral resistance in the presence or absence of ribonuclease L: HSV-1 replication is particularly sensitive to deficiency of the major IFN-mediated enzymes.

Authors:  K S Khabar; M Dhalla; Y Siddiqui; A Zhou; M N Al-Ahdal; S D Der; R H Silverman; B R Williams
Journal:  J Interferon Cytokine Res       Date:  2000-07       Impact factor: 2.607

10.  Induction of transforming growth factor-beta 1 production in human cells by herpes simplex virus.

Authors:  P Méndez-Samperio; M Hernandez; H E Ayala
Journal:  J Interferon Cytokine Res       Date:  2000-03       Impact factor: 2.607

View more
  26 in total

1.  Interferon-beta suppresses herpes simplex virus type 1 replication in trigeminal ganglion cells through an RNase L-dependent pathway.

Authors:  Daniel J J Carr; Khaldun Al-khatib; Cassandra M James; Robert Silverman
Journal:  J Neuroimmunol       Date:  2003-08       Impact factor: 3.478

2.  Inhibition of cellular 2'-5' oligoadenylate synthetase by the herpes simplex virus type 1 Us11 protein.

Authors:  Ricardo Sànchez; Ian Mohr
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

3.  Suppression of the interferon-mediated innate immune response by pseudorabies virus.

Authors:  Alla Brukman; L W Enquist
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  Intact TRL 9 and type I interferon signaling pathways are required to augment HSV-1 induced corneal CXCL9 and CXCL10.

Authors:  Todd Wuest; Bobbie Ann Austin; Satoshi Uematsu; Manoj Thapa; Shizuo Akira; Daniel J J Carr
Journal:  J Neuroimmunol       Date:  2006-08-01       Impact factor: 3.478

5.  VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis.

Authors:  Todd R Wuest; Daniel J J Carr
Journal:  J Exp Med       Date:  2009-12-21       Impact factor: 14.307

Review 6.  IFN-α subtypes: distinct biological activities in anti-viral therapy.

Authors:  K Gibbert; J F Schlaak; D Yang; U Dittmer
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

7.  Distinctive roles for 2',5'-oligoadenylate synthetases and double-stranded RNA-dependent protein kinase R in the in vivo antiviral effect of an adenoviral vector expressing murine IFN-beta.

Authors:  Khaldun Al-Khatib; Bryan R G Williams; Robert H Silverman; William Halford; Daniel J J Carr
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

8.  Delivery of Interferon-gamma by an adenovirus vector blocks herpes simplex virus Type 1 reactivation in vitro and in vivo independent of RNase L and double-stranded RNA-dependent protein kinase pathways.

Authors:  Daniel J J Carr; Bobbie A Austin; William P Halford; Patrick M Stuart
Journal:  J Neuroimmunol       Date:  2008-11-29       Impact factor: 3.478

9.  Protein and gene expression of Ca2+ channel isoforms in murine colon: effect of inflammation.

Authors:  Minho Kang; Nemat Morsy; Xiaochun Jin; Florea Lupu; Hamid I Akbarali
Journal:  Pflugers Arch       Date:  2004-12       Impact factor: 3.657

10.  Herpes simplex virus type 2-induced mortality following genital infection is blocked by anti-tumor necrosis factor alpha antibody in CXCL10-deficient mice.

Authors:  Manoj Thapa; Daniel J J Carr
Journal:  J Virol       Date:  2008-08-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.